The U.S. Food and Drug Administration on Sept. 21 approved Incyte Corp.’s cream Opzelura for treating the inflammatory skin condition atopic dermatitis, commonly called eczema, in adolescents and adults with boxed warnings.
On the back of a $135 million public offering in February, rare disease gene therapy company Krystal Biotech Inc. launched subsidiary Jeune Inc. to promote gene therapies for aesthetic skin conditions.
The U.S. Food and Drug Administration approved Italy-based Cassiopea SpA’s acne treatment Winlevi (clascoterone cream 1%).
Eli Lilly and Co. is buying skin disease specialist Dermira Inc. for about $1.1 billion in cash, bolstering the Indianapolis-based drug manufacturer’s arsenal with an experimental therapy for the skin condition atopic dermatitis.
